281 related articles for article (PubMed ID: 24421053)
1. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
Wason JM; Trippa L
Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
[TBL] [Abstract][Full Text] [Related]
2. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.
Lin J; Bunn V
Contemp Clin Trials; 2017 Mar; 54():48-59. PubMed ID: 28089763
[TBL] [Abstract][Full Text] [Related]
3. Multi-arm multi-stage (MAMS) randomised selection designs: impact of treatment selection rules on the operating characteristics.
Choodari-Oskooei B; Blenkinsop A; Handley K; Pinkney T; Parmar MKB
BMC Med Res Methodol; 2024 Jun; 24(1):124. PubMed ID: 38831421
[TBL] [Abstract][Full Text] [Related]
4. Two-stage response adaptive randomization designs for multi-arm trials with binary outcome.
Lu X; Shan G
J Biopharm Stat; 2024 Jul; 34(4):526-538. PubMed ID: 37452825
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian decision-theoretic sequential response-adaptive randomization design.
Jiang F; Jack Lee J; Müller P
Stat Med; 2013 May; 32(12):1975-94. PubMed ID: 23315678
[TBL] [Abstract][Full Text] [Related]
6. A simulation study of outcome adaptive randomization in multi-arm clinical trials.
Wathen JK; Thall PF
Clin Trials; 2017 Oct; 14(5):432-440. PubMed ID: 28982263
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
[TBL] [Abstract][Full Text] [Related]
8. Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
Mossop H; Grayling MJ; Gallagher FA; Welsh SJ; Stewart GD; Wason JMS
Br J Cancer; 2022 Feb; 126(2):204-210. PubMed ID: 34750494
[TBL] [Abstract][Full Text] [Related]
9. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials.
Thall P; Fox P; Wathen J
Ann Oncol; 2015 Aug; 26(8):1621-8. PubMed ID: 25979922
[TBL] [Abstract][Full Text] [Related]
10. Bayesian adaptive designs for multi-arm trials: an orthopaedic case study.
Ryan EG; Lamb SE; Williamson E; Gates S
Trials; 2020 Jan; 21(1):83. PubMed ID: 31937341
[TBL] [Abstract][Full Text] [Related]
11. A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis.
Bratton DJ; Phillips PP; Parmar MK
BMC Med Res Methodol; 2013 Nov; 13():139. PubMed ID: 24229079
[TBL] [Abstract][Full Text] [Related]
12. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example.
Ryan EG; Bruce J; Metcalfe AJ; Stallard N; Lamb SE; Viele K; Young D; Gates S
BMC Med Res Methodol; 2019 May; 19(1):99. PubMed ID: 31088354
[TBL] [Abstract][Full Text] [Related]
13. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
Trials; 2014 Feb; 15():68. PubMed ID: 24571662
[TBL] [Abstract][Full Text] [Related]
14. Bayesian adaptive randomization designs for targeted agent development.
Lee JJ; Xuemin Gu ; Suyu Liu
Clin Trials; 2010 Oct; 7(5):584-96. PubMed ID: 20571130
[TBL] [Abstract][Full Text] [Related]
15. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma.
Trippa L; Lee EQ; Wen PY; Batchelor TT; Cloughesy T; Parmigiani G; Alexander BM
J Clin Oncol; 2012 Sep; 30(26):3258-63. PubMed ID: 22649140
[TBL] [Abstract][Full Text] [Related]
16. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
[TBL] [Abstract][Full Text] [Related]
17. An overview of methodological considerations regarding adaptive stopping, arm dropping, and randomization in clinical trials.
Granholm A; Kaas-Hansen BS; Lange T; Schjørring OL; Andersen LW; Perner A; Jensen AKG; Møller MH
J Clin Epidemiol; 2023 Jan; 153():45-54. PubMed ID: 36400262
[TBL] [Abstract][Full Text] [Related]
18. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian response-adaptive trial in tuberculosis: The endTB trial.
Cellamare M; Ventz S; Baudin E; Mitnick CD; Trippa L
Clin Trials; 2017 Feb; 14(1):17-28. PubMed ID: 27559021
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian adaptive design for biomarker trials with linked treatments.
Wason JM; Abraham JE; Baird RD; Gournaris I; Vallier AL; Brenton JD; Earl HM; Mander AP
Br J Cancer; 2015 Sep; 113(5):699-705. PubMed ID: 26263479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
